{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix B: The Dermatology Life Quality Index (DLQI) (Continued)', 'Please check one box for each question.', '8.', 'Over the last week, how much has your skin created problems', 'Very much A lot', '-', '-', 'with your partner or any of your close friends or relatives?', 'A little Not at all', 'Not relevant', '-', '-', '-', '9.', 'Over the last week, how much has your skin caused any', 'Very much A lot', '-', '-', 'sexual difficulties?', 'A little Not at all', 'Not relevant', '-', '-', '-', 'Over the last week, how much of a problem has the', '10.', 'Very much A lot', 'treatment for your skin been, for example, by making your', '-', '-', 'A little Not at all', 'Not relevant', 'home messy, or by taking up time?', '-', '-', '-', 'Source: Finlay, 1994.', 'Confidential and Proprietary', '76', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix C: Static Physicians Global Assessment (sPGA) Of Visible', 'Locations', 'The sPGA is the assessment by the Investigator of the overall disease severity at the time of', 'evaluation. In this study, sPGA is used to evaluate psoriasis only in visible locations, defined as', 'dorsal hand, face, neck and hairline.', 'Score', 'Category', 'Description', 'Plaque elevation = 0 (no elevation over normal skin)', '0', 'Clear', 'Scaling = 0 (no evidence of scaling)', 'Erythema = 0 (except for residual hyperpigmentation/', 'hypopigmentation)', 'Plaque elevation = (possible but difficult to ascertain whether', 'there is a slight elevation above normal skin)', '1', 'Almost Clear', 'Scaling = + (surface dryness with some desquamation)', 'Erythema = + (faint, diffuse pink or slight red coloration)', 'Plaque elevation = slight (slight but definite elevation, typically', 'edges are indistinct or sloped)', '2', 'Mild', 'Scaling = fine (fine scale partially or mostly covering lesions)', 'Erythema = mild (light red coloration)', 'Plaque elevation = marked (marked definite elevation with rough', 'or sloped edges)', '3', 'Moderate', 'Scaling = coarser (coarser scale covering most or all of the', 'lesions)', 'Erythema = moderate (definite red coloration)', 'Plaque elevation = marked (marked elevation typically with hard', 'or sharp edges)', '4', 'Severe', 'Scaling = coarser (coarse, non tenacious scale predominates', 'covering most or all of the lesions)', 'Erythema = severe (very bright red coloration)', 'Source: Walsh, 2013.', 'Confidential and Proprietary', '77', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix D: Scalp Physician Global Assessment (ScPGA)', 'Score', 'Category', 'Category Description', '0', 'Clear', 'Scalp Plaque Elevation = 0 (no elevation over normal skin)', 'Scalp Scaling = 0 (no evidence of scaling)', 'Scalp Erythema = 0 (except for residual', 'lyperpigmentation/hypopigmentation)', '1', 'Almost', 'Scalp Plaque Elevation = (possible but difficult to ascertain', 'Clear', 'whether there is a slight elevation above normal skin)', 'Scalp Scaling = (surface dryness with some desquamation)', 'Scalp Erythema = (faint, diffuse pink or slight red coloration)', '2', 'Mild', 'Scalp Plaque Elevation = slight (slight but definite elevation,', 'typically edges are indistinct or sloped)', 'Scalp Scaling = fine (fine scale partially or mostly covering lesions)', 'Scalp Erythema = mild (light red coloration)', '3', 'Moderate', 'Scalp Plaque Elevation = marked (marked definite elevation with', 'rough or sloped edges)', 'Scalp Scaling = coarser (coarser scale covering most or all of the', 'lesions)', 'Scalp Erythema = moderate (definite red coloration)', '4', 'Severe', 'Scalp Plaque Elevation = marked (marked elevation typically with', 'hard or sharp edges)', 'Scalp Scaling = coarser (coarse, non tenacious scale predominates', 'covering most or all of the lesions)', 'Scalp Erythema = severe (very bright red coloration)', 'Confidential and Proprietary', '78', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix E: Nail Psoriasis Severity Index (NAPSI)', 'The target thumb or finger nail which represents the worst nail', 'psoriasis is graded for nail matrix psoriasis and nail bed psoriasis.', 'The sum of these two scores is the total score for that nail.', 'Evaluation 1: Nail matrix. In each quadrant of', 'the nail, nail matrix psoriasis is evaluated by', 'presence of any of the nail matrix features', '(pitting, leukonychia red spots in the lunula,', 'crumbling):', 'Score for nail matrix psoriasis', '0 = none', '1 = present in 1/4 nail', '2 = present in 2/4 nail', '3 = present in 3/4 nail', '4 = present in 4/4 nail', 'Evaluation 2: Nail bed. Nail bed psoriasis is', 'evaluated by the presence of any of the nail bed', 'features (onycholysis, splinter hemorrhages,', 'subungual hyperkeratosis, \"oil drop\" (salmon', 'patch dyschroma):', 'Score for nail bed psoriasis', '0 = none', '1 = present in 1/4 nail', '2 = present in 2/4 nail', '3 = present in 3/4 nail', '4 = present in 4/4 nail', 'TOTAL FOR NAIL', '(0-8)', 'Source: Rich, 2003.', 'Confidential and Proprietary', '79', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}